Clene Inc. (CLNN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Clene Inc. stock (CLNN) is currently trading at $5.73. Clene Inc. PS ratio (Price-to-Sales) is 313.60. Analyst consensus price target for CLNN is $30.33. WallStSmart rates CLNN as Sell.
- CLNN PE ratio analysis and historical PE chart
- CLNN PS ratio (Price-to-Sales) history and trend
- CLNN intrinsic value — DCF, Graham Number, EPV models
- CLNN stock price prediction 2025 2026 2027 2028 2029 2030
- CLNN fair value vs current price
- CLNN insider transactions and insider buying
- Is CLNN undervalued or overvalued?
- Clene Inc. financial analysis — revenue, earnings, cash flow
- CLNN Piotroski F-Score and Altman Z-Score
- CLNN analyst price target and Smart Rating
Clene Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Clene Inc. (CLNN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in eps growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Clene Inc. (CLNN) Key Strengths (1)
Earnings per share surging 61.40% year-over-year
Supporting Valuation Data
Clene Inc. (CLNN) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -15.40%, a shrinking business
Very expensive at 313.6x annual revenue
Very expensive at 7.8x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Clene Inc. (CLNN) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth. Growth metrics are encouraging with EPS Growth at 61.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (313.60), Price/Book (7.83) suggest expensive pricing. Growth concerns include Revenue Growth at -15.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -1738.00%, Operating Margin at -9734.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1738.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -15.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLNN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CLNN's Price-to-Sales ratio of 313.60x trades 84% above its historical average of 170.89x (80th percentile), historically expensive. The current valuation is 60% below its historical high of 793.61x set in Mar 2021, and 5188% above its historical low of 5.93x in May 2024. Over the past 12 months, the PS ratio has expanded from ~110.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Clene Inc. (CLNN) · CONSUMER DEFENSIVE › PACKAGED FOODS
The Big Picture
Clene Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 200,000 with 15% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 2752% of revenue (6M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 15% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor PACKAGED FOODS industry trends, competitive moves, and regulatory changes that could impact Clene Inc..
Bottom Line
Clene Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Clene Inc.(CLNN)
NASDAQ
CONSUMER DEFENSIVE
PACKAGED FOODS
USA
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.